2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Viatris company profile · branded and generic medicines · history · financial snapshot · S&P 500 rank #389 · 暉致公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | VTRS (Nasdaq) |
| Company | Viatris Inc. |
| GICS sector / industry | Health Care / Pharmaceuticals |
| S&P 500 rank (by weight) | #389 · 0.03% (Nov 3, 2026) |
| Sector rank (by S&P 500 weight) | #48 in Health Care (Nov 3, 2026) |
| Headquarters | Canonsburg, Pennsylvania |
| Founded | November 16, 2020 (merger of Mylan and Upjohn) |
| CEO | Scott A. Smith (since April 1, 2023) |
| Employees | Approximately 30,000 |
| Market cap | $21.73B (Nov 3, 2026) |
| SEC filings | EDGAR — CIK 1792044 |
WHAT IT DOES
Viatris is a global healthcare company that bridges brands and generics: it sells off-patent branded medicines, complex generics, biosimilars and over-the-counter products in more than 165 countries, built on a portfolio of more than 1,400 approved molecules. It was formed on November 16, 2020, when Pfizer’s Upjohn business merged with Mylan in a Reverse Morris Trust transaction.
The company reports by geography, not by product type: Developed Markets (North America and Europe), Greater China, JANZ (Japan, Australia and New Zealand) and Emerging Markets. By product category in FY2025, Brands contributed $9,184.0m of net sales (about flat year over year) and Generics $5,066.4m (down 8%), and new-product revenues were approximately $324m for the year.
In 2025 Viatris completed an enterprise-wide strategic review, expecting $650m of total cost savings with reinvestment of up to $250m over three years, and returned more than $1 billion to shareholders. In October 2026 it announced the acquisition of Pacira Biosciences for $1.65 billion, expected to close by the end of 2026 subject to conditions — a post-fiscal-year event not reflected in the FY2025 financial statements.
NET SALES BY SEGMENT — FY2025
| Segment | Net sales | Share | YoY |
|---|---|---|---|
| Developed Markets | $8,514.0m | 59.7% | -5% |
| Greater China | $2,332.5m | 16.4% | +8% |
| JANZ | $1,193.8m | 8.4% | -11% |
| Emerging Markets | $2,210.1m | 15.5% | -2% |
| Total net sales | $14,250.4m | 100% | -3% |
HISTORY
| Year | Milestone |
|---|---|
| 1886 | The Upjohn Company founded in Kalamazoo, Michigan (Upjohn predecessor) |
| 1961 | Mylan founded by Milan Puskar and Don Panoz |
| 2020 | Viatris formed on November 16, 2020, by the merger of Mylan and Pfizer’s Upjohn business; Michael Goettler becomes first chief executive officer |
| 2023 | Scott A. Smith becomes chief executive officer on April 1, 2023, succeeding Michael Goettler |
| 2025 | Enterprise-wide strategic review completed; $2.9 billion goodwill impairment recognised at the March 31, 2025 interim test |
| 2026 | Acquisition of Pacira Biosciences for $1.65 billion announced on October 12, 2026, expected to close by end of 2026 |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025 (10-K)
| Total revenues | $14,299.9m |
| Total net sales | $14,250.4m |
| Gross profit | $5,013.5m |
| Operating income | $254m |
| Net loss | $(3,514.9)m |
| Diluted EPS | $(3.00) |
| Adjusted EBITDA (non-GAAP) | $4,160.0m |
| Adjusted EPS (non-GAAP) | $2.35 |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Viatris is the S&P 500 health-care name where revenue and weight diverge most in this batch: $14.3 billion of sales against a $21.73 billion capitalisation and a #389 rank — the market prices it as a melting ice cube, not as a growth stock.
For the index, it is the test of whether an off-patent portfolio can be stabilised: if brands hold and new products scale, the gap between its $14.3 billion revenue base and its 0.03% weight closes; if generics erosion continues, the weight is telling the truth.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 crawl) · StockAnalysis (market cap — Nov 3, 2026 crawl, single source) |
| Financials | Viatris Inc. Form 10-K for the fiscal year ended December 31, 2025 (filed February 2026) |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | VTRS(Nasdaq) |
| 公司 | Viatris Inc. |
| GICS 板塊/行業 | 醫療保健/Pharmaceuticals |
| 標普500排名(按權重) | 第389名 · 0.03%(2026 年 11 月 3 日) |
| 板塊內排名(按標普500權重) | 醫療保健第48名(2026 年 11 月 3 日) |
| 總部 | 賓夕法尼亞州卡農斯堡 |
| 成立 | 2020年11月16日(Mylan 與 Upjohn 合併) |
| 行政總裁 | Scott A. Smith(2023年4月1日起) |
| 員工 | 約30,000人 |
| 市值 | $21.73B(2026 年 11 月 3 日) |
| SEC 文件 | EDGAR — CIK 1792044 |
業務概覽
暉致是一家橫跨品牌藥及學名藥的全球醫療保健公司,在逾 165 個國家銷售專利屆滿品牌藥、複雜學名藥、生物相似藥及非處方產品,組合涵蓋逾 1,400 個已獲批分子。公司於 2020 年 11 月 16 日成立,由輝瑞的 Upjohn 業務與 Mylan 以反向莫里斯信託交易合併而成。
公司按地區而非產品類型列報:Developed Markets(北美及歐洲)、Greater China、JANZ(日本、澳洲及新西蘭)及 Emerging Markets。按產品類別計,2025 財年 Brands 淨銷售額為 91.840 億美元(按年大致持平),Generics 為 50.664 億美元(下跌 8%);全年新產品收入約 3.24 億美元。
2025 年,暉致完成全企業策略檢討,預期三年內節省合共 6.50 億美元成本,並再投資最多 2.50 億美元;全年向股東返還逾 10 億美元。2026 年 10 月,公司公布以 16.5 億美元收購 Pacira Biosciences,預計於 2026 年底前完成(須符合若干條件)——此為財年結束後事件,並未反映於 2025 財年財務報表。
按分部劃分的淨銷售額 — 2025 財年
| 板塊 | 淨銷售額 | 佔比 | 同比 |
|---|---|---|---|
| Developed Markets | 85.140億美元 | 59.7% | -5% |
| Greater China | 23.325億美元 | 16.4% | +8% |
| JANZ | 11.938億美元 | 8.4% | -11% |
| 新興市場 | 22.101億美元 | 15.5% | -2% |
| 淨銷售總額 | 142.504億美元 | 100% | -3% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1886年 | Upjohn Company 在密歇根州卡拉馬祖成立(Upjohn 前身) |
| 1961年 | Mylan 由 Milan Puskar 及 Don Panoz 創立 |
| 2020年 | 暉致於 2020 年 11 月 16 日由 Mylan 與輝瑞 Upjohn 業務合併而成;Michael Goettler 出任首任行政總裁 |
| 2023年 | Scott A. Smith 於 2023 年 4 月 1 日出任行政總裁,接替 Michael Goettler |
| 2025年 | 完成全企業策略檢討;於 2025 年 3 月 31 日中期測試確認 29 億美元商譽減值 |
| 2026年 | 於 2026 年 10 月 12 日公布以 16.5 億美元收購 Pacira Biosciences,預計於 2026 年底前完成 |
競爭地位
財務快照 — 2025 財年(10-K)
| 總收入 | 142.999億美元 |
| 淨銷售總額 | 142.504億美元 |
| 毛利 | 50.135億美元 |
| 經營利潤 | 2.54億美元 |
| 淨虧損 | (35.149億美元) |
| 攤薄每股盈利 | (3.00美元) |
| 經調整 EBITDA(非公認會計原則) | 41.600億美元 |
| 經調整每股盈利(非公認會計原則) | 2.35美元 |
主要風險
對標普500的重要性
暉致是本批中收入與權重分歧最大的標普 500 醫療保健名稱:銷售額 143 億美元,對比市值 217.3 億美元及第 389 名排名——市場將其定價為正在融化的冰塊,而非增長股。
對指數而言,它是專利屆滿組合能否穩定的檢驗:若品牌藥守得住、新產品擴大規模,其 143 億美元收入基礎與 0.03% 權重之間的差距便會收窄;若學名藥侵蝕持續,則權重說的是實話。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日抓取)· StockAnalysis(市值——2026 年 11 月 3 日抓取,單一來源) |
| 財務 | Viatris Inc. 截至 2025 年 12 月 31 日財年的 Form 10-K(2026 年 2 月提交) |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 18:04 · updated 2026-11-15 00:15 · rev 5